TCL Archive Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent January 8, 1982
TCL Archive Amgen Replaces “Bundling” Contract With Three Separate Contracts For Growth Factors. September 5, 2008
TCL Archive Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products. April 22, 2005
TCL Archive NCI Programs: Director Challenges Scientists To Develop Molecular “Fingerprints” Of Tumors December 4, 1998
